Deep Intelligent Pharma Raises $60M to Build AGI-Powered Digital Scientist Teams for Drug Development

# Deep Intelligent Pharma Raises $60M to Build AGI-Powered Digital Scientist Teams for Drug Development Singapore-based AI pharmaceutical unicorn Deep Intelligent Pharma has secured $60 million in new funding, marking its second major raise in less than two months and bringing total recent capital to over $100 million. The financing round attracted new investors Trustar Capital, Jinyi Capital, and Kaitai Capital, while existing backers CDH Investments and Xinding Capital increased their stakes. The company is pioneering a radical departure from conventional AI applications in drug development. While most competitors focus on narrow pre-clinical tasks, Deep Intelligent Pharma has built what it calls "digital scientist teams"—autonomous AI agent clusters that handle the entire pharmaceutical development lifecycle, from pre-clinical research through regulatory submission, clinical trials, and post-marketing studies. ## Zero-Revision Clinical Protocols The company's most striking achievement is its track record of generating clinical trial protocols that pass regulatory review without a single revision. This "zero-revision" capability demonstrates industrial-grade precision rarely seen in AI applications, where hallucinations and errors typically require extensive human oversight. Deep Intelligent Pharma attributes this reliability to its "bionic brain" architecture—a decentralized network of tens of thousands of specialized AI agents that collaborate like neurons in a human brain. Protocol Agents design trials, Statistical Agents perform quantitative analysis, and Regulatory Agents ensure global compliance. These agents engage in continuous hypothesis-validation-reflection-correction loops, with medical terminology accuracy exceeding 99%. ## Self-Evolving Intelligence What sets the platform apart is its capacity for autonomous learning and self-improvement. Drawing on brain science principles, the system automatically triggers reflection mechanisms when errors occur, performing root-cause analysis to determine whether mistakes stem from missing knowledge or flawed reasoning. It then traces problems to specific agents or decision nodes and autonomously rewrites its own code to eliminate the flaw. This self-correcting capability means the system becomes more capable with use—a key characteristic of artificial general intelligence (AGI) that most current AI systems lack. To address the critical issue of AI hallucinations in high-stakes medical contexts, Deep Intelligent Pharma has implemented a four-layer safeguard system spanning training, inference, cross-validation, and post-processing, achieving what the company claims is 99.9% accuracy at industrial scale. ## Virtual Clinical Trials The company's latest innovation, Protocol Rehearsal, enables pharmaceutical companies to conduct "virtual clinical trials" before enrolling real patients. By simulating trial outcomes, the system can predict enrollment speed, dropout risk, and resource bottlenecks, potentially accelerating the notoriously slow and expensive clinical trial process. This capability could fundamentally transform pharmaceutical development from a labor-intensive industry into one driven by autonomous, intelligent decision-making—a shift investors are betting will create enormous value. ## Industry Transformation "Deep Intelligent Pharma's rapid AI iteration and multi-agent collaboration capabilities are fundamentally reshaping industry cost structures and operating models," said Zhao Lei, Partner at Trustar Capital. The company has already achieved commercialization and profitability, a rarity among AI startups. The rapid-fire fundraising—$50 million in December 2025 followed by $60 million in February 2026—signals strong investor conviction that AGI applications in specialized domains like pharmaceutical research may arrive sooner than general-purpose AGI. By focusing on a high-value, highly regulated industry where precision and reliability are paramount, Deep Intelligent Pharma is demonstrating that the path to AGI may run through vertical specialization rather than horizontal generalization. The new capital will fund upgrades to the company's core technology systems as it pursues global expansion in the pharmaceutical R&D market.